Cargando…
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment
BACKGROUND: Brain volume loss is an important surrogate marker for assessing disability in MS; however, contribution of gray and white matter to the whole brain volume loss needs further examination in the context of specific MS treatment. OBJECTIVES: To examine whole and segmented gray, white, thal...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303064/ https://www.ncbi.nlm.nih.gov/pubmed/30576361 http://dx.doi.org/10.1371/journal.pone.0209326 |